Clinical Trial Update: Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis [Phase 4]

View source ↗

Summary

The Phase 4 open-label trial evaluating cenegermin (rhNGF) for corneal thickness in neurotrophic keratitis via AS-OCT has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Ulcer
• Neurotrophic Keratitis

Drugs mentioned

• cenegermin (cenegermin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Neurotrophic Keratitis, Neurotrophic Keratopathy | Phase 4 | Status: WITHDRAWN